Neuraxis

Neuraxis Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Neuraxis (NRXS) as of Nov 17, 2026 is 76.36. In the previous year, Cash Conversion Cycle (CCC) was -523.96 — a change of -114.57% (higher).

Cash Conversion Cycle

76.36

YoY

-114.57%

Last updated:

Cash Conversion Cycle (CCC) of Neuraxis is 2025 76.36 . Cash Conversion Cycle (CCC) of Neuraxis was 2024 -523.96 . It decreases by -114.57% higher compared to the previous year.

The Neuraxis Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2020
14.83 USD
Jan 1, 2021
-330.92 USD
Jan 1, 2022
-1,873.99 USD
Jan 1, 2023
-1,412.58 USD
Jan 1, 2024
-523.96 USD
Jan 1, 2025
76.36 USD
The Neuraxis Cash Conversion Cycle history
YEARCash Conversion CycleYoY
76.36-114.57%
-523.96-62.91%
-1,412.58-24.62%
-1,873.99+466.30%
-330.92-2,330.78%
14.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Cash Conversion Cycle (CCC) of Neuraxis is 76.36 in 2025.

Cash Conversion Cycle (CCC) of Neuraxis changed from -523.96 to 76.36, representing a -114.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis